File downloaded on 2026-11-07
Source URL: https://medicines.health.europa.eu/veterinary/en/600000033170

Salmoporc, lyophilisate and solvent for suspension for injection for pigs

Authorised

- Salmonella enterica, subsp. enterica, serovar Typhimurium, strain 421/125 (histidine-adenine auxotrophic), Live

Product identification

Medicine name:
Salmoporc, lyophilisate and solvent for suspension for injection for pigs

Active substance:
Salmonella enterica, subsp. enterica, serovar Typhimurium, strain 421/125 (histidine-adenine auxotrophic), Live

Target species:
Pig

Route of administration:
Oral use
Subcutaneous use

Product details

Active substance and strength:

Salmonella enterica, subsp. enterica, serovar Typhimurium, strain 421/125 (histidine-adenine auxotrophic), Live
8.00 log10 colony forming unit(s) / 1.00 millilitre(s)

Pharmaceutical form:
Lyophilisate for suspension for injection

Withdrawal period by route of administration:

Oral use:

- **Pig**
  - Meat and offal. 6 week — six weeks after the second vaccination

Subcutaneous use:

- **Pig**
  - Meat and offal. 6 week — six weeks after the second vaccination

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI09AE02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Portugal

Available in:
Portugal

Package description:
Cardboard box containing 1 vial with 20 doses (1 dose = 1 ml) lyophilised vaccine
1 vial with 20 ml solvent

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Similar biological application (Article 13(4) of Directive No 2001/82/EC)

Marketing authorisation holder:
Ceva Saude Animal Produtos Farmaceuticos E Imunologicos Lda.

Marketing authorisation date:
21/02/2019

Manufacturing sites for batch release:
Ceva-Phylaxia Zrt.
IDT Biologika GmbH

Responsible authority:
Directorate General For Food And Veterinary

Authorisation number:
966/01/19DIVPT

Date of authorisation status change:
4/11/2022

Reference member state:
Netherlands

Procedure number:
NL/V/0247/001

Concerned member states:
Austria Belgium Czechia Denmark Hungary Ireland Italy Portugal Romania Slovakia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet